Navigation Links
Ambit Biosciences to Present at 30th Annual J.P. Morgan Healthcare Conference
Date:1/9/2012

SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Ambit Biosciences Corporation today announced that the company is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at 10 a.m. PST on Thursday, January 12, at The Westin St. Francis in San Francisco. Michael A. Martino, president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib.

About Quizartinib

Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as monotherapy treatment for adult and elderly patients with relapsed/refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.

About Ambit Biosciences

Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and AC480, a pan-HER inhibitor.

Ambit's preclinical portfolio includes, CEP-32496, a BRAF inhibitor licensed to Cephalon, and a proprietary CSF1R inhibitor program. For more information, visit www.ambitbio.com.

Contacts:
Ambit Biosciences:
Alan Fuhrman
Chief Financial Officer
(858) 334-2133

Ian Stone or David Schull (Media)
Russo Partners
(619) 308-6541
(212) 845-4271
ian.stone@russopartnersllc.com
david.schull@russopartnersllc.com

Cindy McGee (Investors)
Russo Partners
(619) 308-6538
cindy.mcgee@russopartnersllc.com

 


'/>"/>
SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
2. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
3. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. Ambit Biosciences Strengthens Board of Directors and Executive Team
6. Ambit Biosciences Initiates Two Phase I Clinical Trials
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
(Date:5/3/2016)... Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. Photo ... ... ... ... Sino-German High-Tech Fund (SGHF) is ...
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016   ... the importance of extending care beyond the implant at ... Sessions, May 4-7 in San Francisco ... with continually delivering the highest quality of patient care ... patients are cared for each and every tomorrow," said ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Standard Process Inc. ... the United States. The whole food nutrient solutions company can help veterinarians grow ... cat and horse owners’ peace of mind. With the increased support, veterinarian customers ...
(Date:5/5/2016)... ... 2016 , ... In order to increase comfort, convenience and ... Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ , a new ... app, developed for both smartphones and personal computers perfectly emulates that of the ...
(Date:5/5/2016)... ... 05, 2016 , ... When stiff and achy joints are ... pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies point to ... , “Physical therapy exercises are commonly prescribed to individuals with osteoarthritis as ...
(Date:5/5/2016)... ... May 05, 2016 , ... VisualDx ... Android devices. VisualDx is the first point of care diagnostic support system ... medicine. The system speeds diagnosis, therapy decisions and patient education for emergency ...
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind ... on your skin, you may want to consider a treatment that some have called ... Advanced Dermatology P.C. , Microneedling, also known as skin needling, is a procedure ...
Breaking Medicine News(10 mins):